Knight Initiative News

Supported by the Big Ideas in Neuroscience program, research from the Brunet lab suggests the possibility of designing pharmaceutical or genetic therapies to turn on new neuron production in old or injured brains.

Stanford undergraduates and local community college students showcased their summer research projects at the Wu Tsai Neurosciences Institute, highlighting efforts to introduce students to neuroscience research for the first time.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.

Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques.

Research by Kati Andreasson and colleagues suggests that a type of drug developed for treating cancer may hold promise as a new treatment for neurodegenerative disorders such as Alzheimer’s.

A drug that restores brain metabolism in mouse models of Alzheimer's also improved cognitive function, according to research from the Andreasson lab.

A team of neuroscientists at the Knight Initiative for Brain Resilience have zeroed in on a critical regulator of brain metabolism that may be over-activated in the brains of patients with Alzheimer’s disease.

Time marches on predictably, but biological aging is anything but constant, according to new research by Michael Snyder and colleagues.

The Knight Initiative's Year-End Symposium and Research Showcase featured a wide range of promising new approaches to understanding brain aging, resilience, and neurodegeneration.

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.

Ten early career neuroscientists received the prestigious award from The McKnight Endowment Fund for Neuroscience.

Pro-inflammatory protein TREM1 in peripheral immune cells may promote age-related cognitive decline and dementia, according to Knight Initiative–funded research.

Recent research supported by the Knight Initiative has identified a link between lipid droplets in the microglia to a known genetic risk factor for AD.

Two new studies supported by the Knight Initiative highlight groundbreaking new early biomarkers for the diagnosis and treatment of neurodegenerative disease.

Research supported by the Knight Initiative found that metformin, a commonly prescribed diabetes drug associated with moderate weight loss, stimulates the production of lac-phe, a molecule abundant after exercise.

This week, I join my producer Michael Osborne on his podcast, Famous and Gravy, to discuss the late, great neuroscientist and author Oliver Sacks.

This week, we sit down with neuroscientist Tony Wyss-Coray to learn about how some of your organs may be aging faster than the rest of you.

This week on From Our Neurons to Yours, we sit down with Stanford neurologist Kathleen Poston to learn about a sea change in our understanding of Parkinson's Disease.

Disabling the notorious APOE4 gene might protect against the disease, according to research from Michael Greicius and team.

We are proud to welcome the 2024 Neurosciences Postdoctoral Scholars — ten young scientists pursuing novel, multi-disciplinary approaches to understanding the workings of the brain.